Cephalon Inc. (CEPH) news stock charts
Cephalon Inc. (CEPH) Investment Summary:
Cephalon, Inc., a biopharmaceutical company, engages in the discovery, development, and marketing of products to treat human diseases in the United States and internationally. The company primarily focuses on four therapeutic areas: central nervous system disorders, pain, oncology, and addiction. Its products for central nervous system disorders include PROVIGIL, for improving wakefulness in patients with excessive daytime sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome (OSA/HS), and shift work sleep disorder; GABITRIL for use as adjunctive therapy in the treatment of partial seizures in epileptic patients; and NUVIGIL, a single-isomer formulation of modafini...www.cephalon.com
3,026 Employees
Founded in 1987
CEPHALON INC (CEPH:NASDAQ)
LAST $70.18 USD
CHANGE TODAY -1.17 -1.64%
VOLUME 1.8M
As of 8:10 PM 03/12/10 All times are local (Market data is delayed by at least 15 minutes).
Snapshot of CEPHALON INC (CEPH)
|
OPEN
$71.35
|
PREVIOUS CLOSE
$71.35
|
|
|
DAY HIGH
$71.35
|
DAY LOW
$69.97
|
|
|
52 WEEK HIGH
03/10/10 - $71.75
|
52 WEEK LOW
07/13/09 - $52.55
|
|
|
MARKET CAP
5.3B
|
AVERAGE VOLUME 10 D
1.6M
|
|
|
EPS TTM
$5.82
|
SHARES OUTSTANDING
74.9M
|
|
|
CEPH Does Not Pay Dividends
|
P/E TTM
12.1x
|
|
| K = Thousands M = Millions B = Billions | ||
related news
No Market Love for These Value-Creating Stocks
12/28/2009 7:35 PM ET
The 10Q Detective: Losing Sleep Over Cephalon
09/28/2009 7:50 PM ET
The 10Q Detective: Losing Sleep Over Cephalon
09/28/2009 7:50 PM ET
Drug, Biotech Research Spending Hangs Tough
08/27/2009 7:43 PM ET
related news
Xoma 4Q profit falls as contract revenue tumbles
AP Digital - 03/11/2010 5:49 PM ET
Key developments for CEPHALON INC (CEPH)
Cephalon Inc. Presents at 19th Annual Partnerships in Clinical Trials, Apr-13-2010
02/17/2010
Cephalon Inc. Presents at 19th Annual Partnerships in Clinical Trials, Apr-13-2010. Venue: Orlando World Center Marriott Resort, 8701 World Center Drive, Orlando, FL 32821, United States. Speakers: Juergen Schmider MD, PhD, Corporate Safety Officer and Vice President Global Pharmacovigilance & Epidemiology.
Cephalon Inc. Presents at 19th Annual Partnerships in Clinical Trials, Apr-14-2010
02/17/2010
Cephalon Inc. Presents at 19th Annual Partnerships in Clinical Trials, Apr-14-2010. Venue: Orlando World Center Marriott Resort, 8701 World Center Drive, Orlando, FL 32821, United States. Speakers: Susan Torchio, Associate Director, Clinical Operations Resourcing & Pain.
Cephalon Inc. Presents at 6th Annual Forum on Late Phase Research, Drug Safety and Risk Management, Feb-25-2010 through Feb-26-2010
02/16/2010
Cephalon Inc. Presents at 6th Annual Forum on Late Phase Research, Drug Safety and Risk Management, Feb-25-2010 through Feb-26-2010. Venue: Le Meridien, 21 Piccadilly, London, W1J 0BH, United Kingdom. Speakers: Juergen Schmider, Corporate Safety Officer and Vice President Global Pharmacovigilance & Epidemiology.
Cephalon Inc. financial resources
CEPH Competitors
| Company | Last | Change |
| CR Bard Inc | $81.98 USD | -0.78 |
| King Pharmaceuticals Inc | $12.36 USD | +0.10 |
| Varian Medical Systems Inc | $52.84 USD | +0.05 |
| Watson Pharmaceuticals Inc | $41.37 USD | +0.39 |
| Market data is delayed at least 15 minutes. | ||
Industry Analysis
| Valuation | CEPH | Industry Range |
| Price/Earnings | 15.9x |
|
| Price/Sales | 2.4x |
|
| Price/Book | 2.3x |
|
| Price/Cash Flow | 15.3x |
|
| TEV/Sales | 1.0x |
|
|
CEPH |
||
|
CEPH transactions
| Type Date |
Target |
|
Merger/Acquisition
February 22, 2010 |
Ception Therapeutics, Inc. |
|
Merger/Acquisition
January 31, 2010 |
Mepha Holding AG |
More Recent Financial News About Cephalon Inc.
Xoma 4Q profit falls as contract revenue tumbles
2010-03-12 01:06:19
Quote: Its revenue fell to $21.6 million from $36.9 million.Analysts polled by Thomson Reuters expected it to post a loss of 3 cents per share on revenue of $15.2 million.Xoma is developing a type 2 diabetes treatment, a potential heart drug, and an anti-botulism antibody.The company has contracts and agreements with Takeda Pharmaceutical Company Ltd., Cephalon Inc., and Kaketsuken, a Japanese research foundation.For the full year, the company earned $550,000, or broke even on earnings per share, compa...Read article
CEPHALON INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
2010-03-01 01:47:59
Quote: CEPHALON INCRequest a Trial to NEW EDGAR Online Pro
Form
8-K for
CEPHALON INC
26-Feb-2010Other Events, Financial Statements and Exhibits
Privacy PolicyAbout Our AdsTerms of ServiceCopyright/IP PolicySend FeedbackSEC
Filing data and information provided by EDGAR Online,
Inc.
(1-800-416-6651). All information provided "as is"
for informational purposes
only, not intended for trading purposes or advice.
Neither Yahoo! nor any of
independent providers is liable for any informational
errors, incomple...Read article
Cephalon exercises $250M option to buy Ception
2010-02-26 07:11:35
Quote: (AP) -- Cephalon will buy Ception Therapeutics Inc. following the successful mid-stage clinical trial of its asthma drug candidate.Tests showed that adults who took the drug Cinquil had greater control over their asthma, the companies said.The companies struck an agreement in January 2009 under which Cephalon paid $100 million for an option to buy Ception at a later date.Cephalon exercised that right and agreed to buy Ception for $250 million, plus any debt held by the company.Ception, based in ...Read article
Cephalon exercises $250M option to buy Ception
2010-02-25 01:32:28
Quote: (AP) -- Cephalon will buy Ception Therapeutics Inc. following the successful mid-stage clinical trial of its asthma drug candidate.Tests showed that adults who took the drug Cinquil had greater control over their asthma, the companies said.The companies struck an agreement in January 2009 under which Cephalon paid $100 million for an option to buy Ception at a later date.Cephalon exercised that right and agreed to buy Ception for $250 million, plus any debt held by the company.Ception, based in ...Read article
Cephalon Exercises its Option to Acquire Ception Therapeutics
2010-02-25 01:32:28
Quote: Lesley Russell, Chief Medical Officer at Cephalon. Â "These data provide confidence that CINQUIL shows a meaningful treatment effect in this patient population. Â We look forward to advancing CINQUIL into Phase three clinical trials."Based on these Phase II results, Cephalon exercised its option to acquire Ception on February 22, 2010. Â Following the exercise of its option, Cephalon's obligation to enter into a merger agreement relating to the acquisition is subject to Cephalon's rights u...Read article
Cephalon Exercises its Option to Acquire Ception Therapeutics
2010-02-24 02:52:10
Quote: Lesley Russell, Chief Medical Officer at Cephalon. Â "These data provide confidence that CINQUIL shows a meaningful treatment effect in this patient population. Â We look forward to advancing CINQUIL into Phase three clinical trials."Based on these Phase II results, Cephalon exercised its option to acquire Ception on February 22, 2010. Â Following the exercise of its option, Cephalon's obligation to enter into a merger agreement relating to the acquisition is subject to Cephalon's rights u...Read article
Cephalon to buy Ception of Malvern for $250M
2010-02-24 02:52:09
Quote: Cephalon Inc. said Tuesday it has exercised its option to acquire Ception Therapeutics Inc. for $250 million, following receipt of positive data from a clinical study of Ception’s lead new drug candidate Cinquil in adults with eosinophilic asthma.“The acquisition of Ception is consistent with our strategy to diversify into biologics and provides us with an important phase-III asset for further development,” said Frank Baldino Jr., chairman and CEO of Cephalon (NASDAQ:CEPH).Ceph...Read article
Cephalon exercises $250M option to buy Ception
2010-02-24 02:52:08
Quote: (AP) -- Cephalon will buy Ception Therapeutics Inc. following the successful mid-stage clinical trial of its asthma drug candidate.Tests showed that adults who took the drug Cinquil had greater control over their asthma, the companies said.The companies struck an agreement in January 2009 under which Cephalon paid $100 million for an option to buy Ception at a later date.Cephalon exercised that right and agreed to buy Ception for $250 million, plus any debt held by the company.Ception, based in ...Read article
Cephalon 4Q profit jumps on sales, lower charges
2010-02-23 01:59:48
Quote: (AP) -- Biotechnology company Cephalon Inc. said Thursday its fourth-quarter profit surged on a boost in sales and lower charges.Cephalon earned $96.6 million, or $1.23 per share, compared with $5 million, or 6 cents per share, a year ago, when the company recorded a series of hefty charges that included impairments on the alcohol addiction treatment Vivitrol.Excluding the charges, the company said it earned $1.66 per share during the most recent quarter, compared with adjusted profit a year pri...Read article
CEPHALON INC Files SEC form 8-K, Change in Directors or Principal Officers
2010-02-22 03:59:51
Quote: Item 5.02Departure of Directors or Principal Officers; Election of
Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers
On January 27, 2010, the Stock Option and Compensation Committee of the Board of
Directors (the "Board") of Cephalon, Inc. (the "Company") determined the
recommended annual cash bonus awards to be made to executive officers of the
Company for fiscal year 2009 as determined pursuant to the Company's Management
Incentive ...Read article
CEPHALON INC Files SEC form 10-K, Annual Report
2010-02-15 04:38:38
Quote: ITEM 7.MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
Management's Discussion and Analysis of Financial Condition and Results of
Operations ("MD&A") is intended to provide information to assist you in better
understanding and evaluating our financial condition and results of operations.
We encourage you to read this MD&A in conjunction with our consolidated
financial statements included in Part II, Item 8 of this Annual Report on
Form 1...Read article
Cephalon Reports Record Sales and Adjusted Net Income for 2009
2010-02-12 06:53:29
Quote: Contacts: Media:Investors:Sheryl WilliamsRobert (Chip) Merritt610-738-6493610-738-6376swilliam@cephalon.comcmerritt@cephalon.comCEPHALON, INC. AND SUBSIDIARIESCONSOLIDATED STATEMENTS OF OPERATIONS(In thousands, except per share data)(Unaudited)Three Months EndedYear EndedDecember 31,December 31,---------------------------------------AsAsadjustedadjusted20092008*20092008*--------------------------REVENUES:Net sales$562,938$534,861$2,151,548$1,943,464Other revenues12,1775,27740,76031,090----------...Read article
UPDATE - Cephalon 2010 forecast tops Street view
2010-02-12 06:53:28
Keywords: Pharmaceuticals (sub-industry),Biotechnology,United States of America,Corporate Results,Corporate Results Forecasts,Healthcare,Business activities,Company News item,Economic news, EC, business/financial pages,
Quote: UPDATE 2-Cephalon 2010 forecast tops Street view
* Sees 2010 sales $2.61 bln to $2.69 bln * Sees 2010 adjusted EPS $6.80 to $7.00 * Street view 2010 sales $2.43 bln, adjusted EPS $6.28 * Shares flat after forecasts(Add analyst comment, sales details, Q4 expectations) By Bill Berkrot NEW YORK, Feb 11 (Reuters) - Drugmaker Cephalon Inc(CEPH.O)
on Thursday issued a 2010 sales and earnings forecast that
exceeded current Wall Street estimates. The company said it expects 2010 sales of $2.61 billion ...Read article
CEPHALON INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Principal Officer
2010-02-12 06:53:28
Quote: Item 1.01Entry into a Material Definitive Agreement.
On February 5, 2010, Cephalon, Inc. (the "Company") and Robert P. Roche, Jr.,
the Company's Executive Vice President, Worldwide Pharmaceutical Operations as
of that date, entered into a consulting agreement (the "Agreement") for a term
beginning February 8, 2010 and ending on August 8, 2010.During the term of the
Agreement, Mr. Roche will assist with the transition of responsibilities with
respect to worldwide pharmaceutic...Read article
Cephalon fourth-quarter profit jumps to $96.6 mln
2010-02-12 06:53:28
Keywords: , CEPH, Cephalon Inc
Quote: SAN FRANCISCO (MarketWatch) -- Cephalon Inc./quotes/comstock/15*!ceph/quotes/nls/ceph(CEPH66.05,+0.54,+0.82%) said late Thursday that its fourth-quarter profit increased to $96.6 million, or $1.23 a share, from $5 million, or 6 cents a share, in the year-ago period. Excluding one-time items, the biotech company would have reported earnings of $1.66 a share. Revenue rose to $575.1 million from $540.1 million a year ago. Analysts surveyed by FactSet Research estimated a quarterly profit of $1.60 a...Read article
Cephalon, Inc. Q4 2009 Earnings Call Transcript
2010-02-12 06:53:27
Quote: Cephalon, Inc. (CEPH)
Q4 2009 Earnings Call Transcript
February 11, 2010 5:00 pm ET
Executives
Chip Merritt – VP, IR
Frank Baldino – Chairman and CEO
Wilco Groenhuysen – EVP & CFO
Bob Repella – SVP and Head of U.S. Pharmaceutical Operations
Lesley Russell – EVP and Chief Medical Officer
Kevin Buchi – EVP and CFO
Analysts
Gary Nachman – Leerink Swann
Manoj Garg – Soleil Securities
Chris Schott – JP Morgan
Marc Goodman – UB...Read article
Cephalon 4Q profit jumps on sales, lower charges
2010-02-12 06:53:27
Quote: (AP) -- Biotechnology company Cephalon Inc. said Thursday its fourth-quarter profit surged on a boost in sales and lower charges.Cephalon earned $96.6 million, or $1.23 per share, compared with $5 million, or 6 cents per share, a year ago, when the company recorded a series of hefty charges that included impairments on the alcohol addiction treatment Vivitrol.Excluding the charges, the company said it earned $1.66 per share during the most recent quarter, compared with adjusted profit a year pri...Read article
Cephalon 4Q Beats the Street; Forecast Tops Estimates
2010-02-12 06:53:27
Keywords: Cephalon 4Q Beats Street; Forecast Tops Estimates, Cephalon Inc., CEPH, guidance, revenue, earnings
Quote: Cephalon Inc. (CEPH) reported earnings that beat analystexpectations and gave full-year revenue guidance that was above the Street’s view.The company expects fiscal 2010 revenue in the range of $2.61 billion to $2.69 billion, beating analyst forecasts for $2.43billion, according to a poll by Thomson Reuters. The company said it expects full-year earnings in the range of $6.80 to $7.00per share, assuming 76.2 million basic shares outstanding as a result of the Mepha acquisition, which clos...Read article
Clinical trial services company BioClinica wins contract with Cephalon
2010-02-05 07:42:54
Quote: said Thursday it has signed a three-year, multimillion-dollar deal to provide end-to-end data management services to pharmaceutical firm Cephalon Inc.’s global clinical trial operations.Under the deal, Newtown, Pa.-based BioClinica (NASDAQ:BIOC) will hire Cephalon’s U.S.-based data-management staff.BioClinica said the deal will extend its role with Frazer, Pa.-based Cephalon (NASDAQ:CEPH) from being a technology provider to being a key services partner.The company will work with othe...Read article
Would you like to leave a comment about Cephalon Inc. CEPH
Find out what social network information about Cephalon Inc. are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides Cephalon Inc.'s Stock there is more great penny stock and market information at Realpennies